B of A Securities Upgrades Tyra Biosciences to Buy, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has upgraded Tyra Biosciences from Neutral to Buy and increased its price target from $22 to $31.
October 18, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has upgraded Tyra Biosciences from Neutral to Buy, raising the price target from $22 to $31, indicating a positive outlook.
The upgrade from Neutral to Buy by a major financial institution like B of A Securities is likely to positively influence investor sentiment and increase buying interest in Tyra Biosciences. The raised price target to $31 suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100